The journal European Neuropsychopharmacology has published a study showing that cannabinoids may provide a treatment option for depression associated with diabetes.
“The pathophysiology associated with increased prevalence of depression in diabetics is not completely understood, although studies have pointed the endocannabinoid system as a possible target”, researchers state. With this in mind, they “aimed to investigate the role of this system in the pathophysiology of depression associated with diabetes.”
Using diabetic rats administered with a natural endocannabinoid, researchers say that their data “suggest that in depression associated with diabetes, the endocannabinoid anandamide has a potential to induce neuroadaptative changes able to improve the depressive-like response by its action as a CB1 receptor agonist.”
Cannabis and its cannabinoid compounds are natural agonists of the CB1 receptor; due to this, the study heavily indicates that cannabis is a potential treatment option for depression associated with diabetes.
The full study can be found by clicking here.